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Purpose: Dynamic contrast-enhanced CT (DCE-CT) quantiﬁes vasculature properties of tumors, whereas
static FDG-PET/CT deﬁnes metabolic activity. Both imaging modalities are capable of showing intra-
tumor heterogeneity. We investigated differences in vasculature properties within primary non-small
cell lung cancer (NSCLC) tumors measured by DCE-CT and metabolic activity from FDG-PET/CT.
Methods: Thirty three NSCLC patients were analyzed prior to treatment. FDG-PET/CT and DCE-CT were
co-registered. The tumor was delineated and metabolic activity was segmented on the FDG-PET/CT in
two regions: low (<50% maximum SUV) and high (P50% maximum SUV) metabolic uptake. Blood ﬂow,
blood volume and permeability were calculated using a maximum slope, deconvolution algorithm and a
Patlak model. Correlations were assessed between perfusion parameters for the regions of interest.
Results: DCE-CT provided additional information on vasculature and tumor heterogeneity that was not
correlated to metabolic tumor activity. There was no signiﬁcant difference between low and high meta-
bolic active regions for any of the DCE-CT parameters. Furthermore, only moderate correlations between
maximum SUV and DCE-CT parameters were observed.
Conclusions: No direct correlation was observed between FDG-uptake and parameters extracted from
DCE-CT. DCE-CT may provide complementary information to the characterization of primary NSCLC
tumors over FDG-PET/CT imaging.
 2013 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 109 (2013) 65–70One of the hallmarks of cancer is angiogenesis [1]. As a result of
the abundant and non-structured production of angiogenic pro-
teins, blood vessels in tumors become abnormal. Paradoxically, tu-
mor angiogenesis therefore leads to hypoxia, one of the most
important triggers for tumor progression, metastasis formation
and treatment resistance [2]. As angiogenesis can indirectly be
quantiﬁed by perfusion, techniques to determine blood ﬂow have
gained increasing interest. 18F-deoxyglucose (FDG) uptake by
means of PET scans is used to stage non-small cell lung cancer
(NSCLC) and has prognostic value as well [3,4]. FDG uptake is re-
lated to many biological processes, including glucose metabolism
and hypoxia [5]. Angiogenesis and FDG uptake thus deﬁne distinct,
though relevant biological processes.With the introduction of the latest state-of-the-art CT scanners,
volumetric imaging using dynamic contrast-enhanced CT imaging
(DCE-CT) of primary lung cancer is now possible [6–8]. Parameters
derived from DCE-CT in NSCLC were previously shown to correlate
with tumor characteristics such as micro vessel density (MVD) [9–
11] and negative correlations between blood vessel permeability
and the glucose transporter (Glut-1) receptor [12] were observed.
Li et al. demonstrated a direct strong correlation between blood
volume and MVD in a heterogeneous group of peripheral lung can-
cers, proposing DCE-CT for the in vivo evaluation of necrosis and
neoangiogenesis [11].
Furthermore, DCE-CT was found to correlate with the gold stan-
dard of perfusion, [(15)O]H2O-PET [13]. Although dynamic FDG
acquisitions may also give insight of tumor perfusion, in routine
clinical practice, static PET scans are used. Static high FDG-uptake
patterns prior to treatment have been shown to identify resistance
areas within a tumor indicated by residual metabolic tumor activ-
ity in follow-up imaging after radiotherapy [14–16]. It is therefore
of interest to investigate the correlations between vasculature
parameters derived from DCE-CT and metabolic imaging parame-
ters from FDG-PET/CT [17]. However, previous studies found mixed
66 FDG-PET and DCE-CT in NSCLCresults, i.e., some studies showing positive [18], others inverse
[19,20] or no correlation [20–22] between FDG-PET and DCE-CT
parameters. Furthermore, typically these studies report only mod-
est correlation coefﬁcients around 0.5. This suggests possible com-
plementary information of DCE-CT compared to FDG-PET imaging,
the ﬁrst one being more speciﬁc for quantiﬁcation of vasculature
properties and the second identifying metabolic status of the tu-
mor. Quantiﬁcation of tumor heterogeneity by combining vascula-
ture and metabolic properties of the tumor could in future be
important factors to use for treatment individualization [23–25].
In the context of radiotherapy of non-small cell lung cancer, few
DCE-CT imaging studies are being performed. Permeability derived
from DCE-CT was hypothesized to relate to tumor response or out-
come after (chemo-)radiotherapy [21,26]. During radiotherapy,
different spatial uptake patterns between the core and the rim of
the tumor were described, with the latter being more vascularized
[27]. However, the authors did not investigate and compare the re-
sults with the FDG-uptake pattern.
The aim of this study was twofold, ﬁrst to investigate the heter-
ogeneity of vasculature within primary NSCLC for various fre-
quently used kinetic algorithms and secondly to compare the
extracted perfusion parameters from DCE-CT with different meta-
bolically active regions deﬁned on FDG-PET.Materials and methods
Patient characteristics
We analyzed advanced stage NSCLC patients (stage II and III)
from two different hospitals. Images were acquired at the Maas-
tricht University Medical Centre (MUMC, Maastricht, The Nether-
lands) (dataset A, NCT01024829 and NCT01210378) and the
Cantonal Hospital Luzern (Switzerland) (dataset B, Cantonal Ethics
Trial Nr.1000) prior to intended (chemo-)radiotherapy treatment.DCE-CT image acquisition
DCE-CT imaging was performed on a second generation dual
source CT scanner (Deﬁnition Flash; Siemens Healthcare, Forch-
heim, Germany) in both centers. Image acquisition was performed
using either 80 kVp/120 mAs (dataset A) or 100 kVp/100 mAs set-
ting (dataset B) using a cranial caudal ﬁeld of view of 13 cm (data-
set A) and 7 cm (dataset B) centered on the primary tumor at a slice
thickness of 5 mm. The ﬁrst 50 s (dataset A) or 60 s (dataset B)
were scanned at a cycle time of 1.5 and 1.0 s per image, for dataset
A and B, respectively, and captured with a delay of two (dataset A)
or three (dataset B) seconds after start of the contrast injection. The
contrast agent was iodine based, either using 60 ml iopromide
(Ultravist 300, Bayer Healthcare, Berlin, Germany) injected at
7.0 ml/s for dataset A or 40 ml (Ultravist 370) injected at 4.5 ml/s
for dataset B. Patients were advised to do a breath-hold at expira-
tion or resume shallow breathing for the entire duration of the
scan. Image reconstruction encompassing the entire thorax was
performed with a 512  512 pixel matrix and (medium) smooth
B20f (dataset A) or B30f (dataset B) kernel.FDG-PET/CT acquisition
On the same day of the DCE-CT, patients underwent an FDG-
PET/CT acquisition on an integrated PET/CT scanner according to
institutional protocols. Image acquisition started 1 h after injection
of approximately 250 MBq FDG (depending on patient weight) on a
Siemens Biograph 40 PET/CT (Siemens Healthcare, Erlangen, Ger-
many) for dataset A or on a GE Discovery 600 PET/CT scanner
(GE Healthcare, Waekesha (WI), USA) for dataset B. Images wereconverted into standardized uptake values (SUV) correcting for in-
jected activity and body weight.DCE-CT and SUV analysis
Tumor volumes of the primary tumor were manually delineated
on the PET/CT scan by experienced radiation oncologists. Tumor
volumes were also classiﬁed as small or large tumors using a
cut-off of 30 cm3 [19]. Metabolic uptake regions within this pri-
mary tumor were automatically segmented using the FDG-PET
images and divided into a low (0–50% of the maximum SUV) and
high metabolic uptake (P50% of the maximum SUV). The 50% SUV-
max cut-off has been hypothesized to contain residual disease after
treatment [15] and is used as target in on-going dose-boosting tri-
als [28]. Additionally, the maximum SUV inside the region of inter-
est was extracted. Furthermore, an analysis according to
histological subtype was performed.
Subsequently, the CT scan of the PET/CT acquisition and the ﬁrst
frame (time point) of the DCE-CT scan were non-rigidly registered
using previous validated in-house developed software [29]. The
contours of the primary tumor, low and high uptake regions on
the PET/CT scan were copied to the DCE-CT. In order to assure cor-
rect calculation, the deformation ﬁelds were visually assessed. By
transferring the contour of the region of interest from one image
set to the other, we prevent interpolation issues from down and
up scaling that might distort the original image (e.g., SUV) values
that could occur if the images themselves are deformed. Parame-
ters from the DCE-CT were calculated using commercial software
(Siemens VPCT body (VE36A), Siemens Healthcare, Forchheim,
Germany). Both motion correction and noise reduction algorithms
implemented in the software were applied. For the arterial input
function a region of interest was chosen inside the aortic arch.
Three kinetic analysis algorithms were calculated: maximum slope
model (S), a deconvolution algorithm (A) and a Patlak (P) analysis.
From these algorithms various parameters for the primary tumor
were extracted. Blood ﬂow (BF) was extracted for the maximum
slope and deconvolution algorithm, blood volume (BV) for all three
algorithms, and a measure of permeability (PMB) was calculated
for the deconvolution and Patlak model. For the primary tumor,
low and high uptake regions, the average blood ﬂow, blood volume
and permeability were calculated. Voxel-by-voxel parameter maps
were exported and combined with the volume of interest deﬁned
on the PET/CT images. Average blood ﬂow, volume and permeabil-
ity parameters were then calculated for the speciﬁc parameter un-
der investigation. Also, correlations between the extracted
parameters within the algorithms and between different kinetic
models were assessed.Statistics
Differences between two groups were compared using a Stu-
dent’s t-test or a one-way ANOVA testing for multiple groups,
whereas paired statistics were calculated using the paired t-test.
Correlations were assessed using linear regression and Pearson’s
coefﬁcient r with r < 0.3 indicating small or no correlation,
0.3 < r < 0.5 for moderate and r > 0.5 for strong correlations. Values
of p < 0.05 were considered as statistically signiﬁcant.
Results
In total 33 patients were included in the analysis, 11 patients
from dataset A and 22 patients from dataset B. There were no sig-
niﬁcant differences between dataset A and B in distribution of the
maximum SUV (p = 0.45) or extracted perfusion parameters (range
p-values: 0.15–0.86), therefore we pooled both datasets for subse-
quent analysis. An example of a patient is shown in Fig. 1.
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tracted within the primary tumor. First, correlation between the
average extracted parameters between different models was as-
sessed. Blood ﬂow correlated strongly between the maximum
slope and deconvolution model, r = 0.91 (p < 0.001), however, the
slope between both models was 2.08 indicating an almost double
parameter estimation for the deconvolution model compared to
the maximum slope model. For blood volume, correlations were
also strong: maximum slope versus deconvolution algorithm:
r = 0.94 (p = 0.001, slope: 1.01); maximum slope versus Patlak:
r = 0.70 (p < 0.001, slope: 0.76); and deconvolution algorithm ver-
sus Patlak: r = 0.72 (p < 0.001, slope: 0.74). For permeability the
correlation parameters were r = 0.68 (p < 0.001), slope: 0.69 be-
tween the deconvolution and Patlak model.
Second, we investigated the correlation between the various
perfusion parameters within one algorithm; see Supplemental
Fig. S1 for the results of the deconvolution algorithm. For the max-
imum slope algorithm (2 kinetic parameters extracted), blood ﬂow
was highly correlated with blood volume (r = 0.91, p < 0.001). For
the deconvolution algorithm (3 parameters estimated), blood ﬂow
and blood volume were also highly correlated (r = 0.77, p < 0.001)
as well as permeability and blood volume (r = 0.71, p < 0.001),
and to a lesser extent also blood ﬂow and permeability (r = 0.59,
p < 0.001; Supplemental Fig. S1). For the Patlak model (2 parame-
ters estimated) blood volume and permeability were not correlated
(r = 0.26, p = 0.15).
There was no statistical difference between perfusion parame-
ters extracted for small or large tumors (p > 0.2 for all parameters;
Table 1). Maximum SUV showed a difference between small and
large tumors: 4.5 ± 2.3 (1 SD) and 6.5 ± 2.8 (p = 0.008), respectively.
In Fig. 2, the (non-) correlation between maximum SUV and
perfusion parameters derived for the deconvolution algorithmFig. 1. DCE-CT and FDG-PETare shown. These correlations were non-signiﬁcant for PMB
(p = 0.13) and only moderately correlated for BF (r = 0.45,
p = 0.008) and BV (r = 0.35, p = 0.04). Similar results, were found
for the maximum slope method (BF: r = 0.35, p = 0.04, BV:
r = 0.41, p = 0.02) and Patlak model (BV: p = 0.07, PMB: r = 0.41,
p = 0.02) showing moderate correlation with the maximum FDG-
uptake.
There was no signiﬁcant difference between the high and low-
uptake FDG regions (Fig. 3 and Table 2). Although permeability ex-
tracted using the deconvolution algorithm showed higher values
for the high metabolic uptake region, this did not reach signiﬁ-
cance (p = 0.08).
Also for histological subtypes, grouped between adenocarci-
noma (N = 15), squamous cell carcinoma (N = 8), large cell carci-
noma (N = 9) and one neuroendocrine tumor, results did not
show statistical differences, see Supplemental Table S1.
Discussion
DCE-CT is a suitable technique for visualization and quantiﬁca-
tion of heterogeneity in vasculature of NSCLC tumors. Blood ﬂow
and volume are both indirect measures of tumor angiogenesis,
which have shown to be measurable with perfusion studies
[30,31]. Perfusion parameters extracted using the frequently used
kinetic models in DCE-CT did not show strong correlations with
static FDG-uptake in primary non-small cell lung cancer tumors
indicating additional quantitative characteristics of the primary tu-
mor. Perfusion parameters within the high and low metabolically
active regions did not show large differences which may suggest
that there is no difference in vasculature between metabolically
active and non-active regions. DCE-CT thus gives additional infor-
mation on vasculature that is not directly related to metabolic tu-example of a patient.
Table 1
Overview of the extracted perfusion parameters for the entire primary tumor, small and large tumors. p-Values are calculated using a t-test between small and large tumors.
All tumors
(N = 33)
Small tumors (<30 cm3)
(N = 8)
Large tumors (>30 cm3)
(N = 25)
Small versus large
tumors
Mean ± SD Mean ± SD Mean ± SD p-Value
Blood ﬂow [ml/100 ml/min] Maximum slope 36.5 ± 20.8 39.2 ± 34.6 35.7 ± 14.9 0.996
Deconvolution
alg.
74.7 ± 47.7 92.7 ± 87.0 68.9 ± 26.1 0.250
Blood volume [ml/100 ml] Maximum slope 7.4 ± 4.0 9.1 ± 6.4 6.9 ± 2.9 0.374
Deconvolution
alg.
8.9 ± 4.3 10.7 ± 5.9 8.4 ± 3.6 0.434
Patlak 7.9 ± 4.4 8.3 ± 4.8 7.8 ± 4.4 0.969
Permeability [ml/100 ml/
min]
Deconvolution
alg.
16.1 ± 10.0 17.9 ± 13.4 15.5 ± 8.9 0.885
Patlak 21.6 ± 9.7 26.4 ± 9.8 20.0 ± 9.3 0.222
FDG-PET [SUV] Mean SUV 6.1 ± 2.8 4.5 ± 2.3 6.5 ± 2.8 <0.001
Maximum SUV 13.8 ± 6.1 9.0 ± 4.8 15.3 ± 5.7 0.008
N, number; SD, standard deviation; alg., algorithm; SUV, standardized uptake value.
Fig. 3. Box-plot of the differences between the calculated perfusion parameters for
the low and high uptake regions inside the primary tumor for the maximum slope
(S), deconvolution algorithm (A) and Patlak model (P). Only maximum SUV showed
a signiﬁcant increase of 108% between both regions (p < 0.001) due to the deﬁnition
of the two regions of interest.
68 FDG-PET and DCE-CT in NSCLCmor activity. Some authors already suggested such a decoupling
between perfusion characteristics and metabolic activity for larger
tumor volumes [19,20]. This is in line with our dataset where even
though the majority of primary tumors were fairly large in size, we
did not observe a correlation between any of the perfusion param-
eters and metabolic activity. Furthermore, this study shows that
besides for tumor size this decoupling might also hold true within
the primary tumor, where no differences were found betweenmet-
abolic (non-) active regions.
There was a high correlation between similar extracted param-
eters on DCE-CT that were calculated using different models, e.g.,
the blood ﬂow extracted using the maximum slope model and
the deconvolution algorithm had a strong correlation. Further-
more, it is worthwhile to note that the deconvolution algorithm
had typically a twice as high value for blood ﬂow. Smaller discrep-
ancies between the various algorithms were found for blood vol-
ume and permeability. This discrepancy has previously been
shown for other software packages and models [32].
There are several restrictions and limitations that have to be ta-
ken into account for the interpretation of DCE-CT studies. First, for
this study we used data from two centers having slightly different
acquisition procedures (e.g., acquisition length, iodine delivery
rates and temporal resolution). However, for the current study
we could not identify a difference in extracted parameters for both
centers. Furthermore, fast CT acquisition techniques can be per-
formed in breath hold or provide a snapshot of the tumor during
the breathing cycle. Compared to a PET technique one has to real-
ize that PET imaging is typically performed using a 3D acquisition
over multiple breathing cycles causing blurring due to breathing
motion and possible patient movement. Hence, registration be-
tween (DCE-)CT and PET/CT images has to be evaluated carefully
especially in transferring regions of interest from one dataset to
the other.Fig. 2. Scatter plot of the extracted kinetic parameters (blood ﬂow (left), blood volume (m
and maximum SUV inside the primary lung tumor.Second, to assess permeability of vasculature typically longer
acquisition times of up to 3 or 5 min have been used, whereas
our perfusion protocols were (ﬁrst-pass) perfusion of the tumor
during the ﬁrst minute after contrast administration. Extending
acquisition time may give better estimations of the permeability
and thus future studies need to be explored whether estimationiddle) and permeability (right panel) calculated using the deconvolution algorithm
Table 2
Overview of the extracted perfusion parameters for the low and high uptake regions inside the primary tumor. p-Values are calculated using a paired t-test between low and high
FDG-uptake values.
Low FDG-uptake region (<50% maximum
SUV)
High FDG-uptake region (>50% maximum
SUV)
Low versus high
uptake
Mean ± SD Mean ± SD p-Value
Blood ﬂow [ml/100 ml/min] Maximum slope 39.0 ± 32.3 39.2 ± 20.8 0.961
Deconvolution
alg.
83.0 ± 62.1 74.6 ± 46.6 0.117
Blood volume [ml/100 ml] Maximum slope 7.8 ± 5.7 8.0 ± 4.0 0.732
Deconvolution
alg.
9.2 ± 5.5 9.6 ± 4.3 0.472
Patlak 8.6 ± 4.6 8.2 ± 5.1 0.547
Permeability [ml/100 ml/
min]
Deconvolution
alg.
15.7 ± 12.9 18.6 ± 13.0 0.080
Patlak 21.4 ± 9.6 22.5 ± 10.2 0.181
FDG-PET [SUV] Mean SUV 4.3 ± 1.8 9.0 ± 3.9 <0.001
Maximum SUV 7.6 ± 3.7 13.8 ± 6.1 <0.001
SD, standard deviation; alg., algorithm; SUV, standardized uptake value.
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with metabolic uptake [30].
Third, validation of kinetic analysis software is not trivial. The
commercial software package we used in this study has been used
by others to compare functional imaging parameters against his-
tology [10]. However, in general, most commercial software solu-
tions are black-box systems with build-in smoothing, noise
reduction and automatic ﬁtting procedures that are not directly
interchangeable [32]. Thorough validation and benchmarking
against other kinetic analysis models, e.g., an extended Tofts model
or approximated adiabatic expansion model are necessary. Select-
ing a sound kinetic analysis model is topic of investigation for var-
ious groups and may need to be tailored to different tumor sites
[33,34].
Lastly, in contradiction to some but not all literature [18,19], we
did not ﬁnd strong correlations between FDG-uptake measured on
PET imaging and perfusion characteristics in non-small cell lung
cancer. Several authors describe signiﬁcant correlations, however,
in our study these correlations appear to be weak or at maximum
modest with moderate correlation coefﬁcients, we therefore can-
not conclude that metabolic and vasculature properties are linked
using the current imaging and analysis methodology. Hence FDG
uptake and perfusion derived parameters show distinct biological
characteristics allowing further characterizing tumor heterogene-
ity that should be investigated in future as an independent factor
for treatment outcome.
With the current frequently used ﬁrst-pass perfusion protocols
no correlation between metabolic uptake visualized on FDG-PET/
CT imaging and extracted DCE-CT parameters was found. Further
research in optimizing the acquisition settings and kinetic analysis
models are necessary for exploration of the added value of DCE-CT
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